KalVista Reports First Quarter Results

From the KalVista Pharmaceuticals, Inc. financial results for the fiscal first quarter ended July 31, 2018:

“Our recent financings provide significant additional capital for late-stage development of KVD900, our oral plasma kallikrein inhibitor for potential treatment of on-demand acute attacks in patients with HAE,” said Andrew Crockett, CEO. Additionally, we remain committed to our work in discovering and developing oral plasma kallikrein inhibitors for prophylactic treatment of HAE. We recently moved to our new facility in Porton Down, England, which is intended to support our scientific team as they continue to work on discovery and development of additional drug programs.”
(Source: KalVista)

2018-09-14T17:11:20+02:00September 14, 2018|HAEi News|